Vivimed Labs has received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad.

1. PRODUCT: Bilastin tablets( Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine Hi receptor antagonist
USES: It is used in the treatment of allergic Rhino conjunctivitis and Urticaria (hives).

2. PRODUCT: Orzole combi
USES: Ofloxacin + Ornidazole is used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

Powered by Capital Market - Live News

The company received approval for Bilastin tablets and Orzole combi. Both the products are manufactured at the company's Hyderabad-based facility that has been approved by PICS & Health Canada.

Bilastin tablets (brand name Flustin) is a second-generation antihistamine used in treating allergic Rhino conjunctivitis and Urticaria (hives).

Orzole combi (Ofloxacin + Ornidazole) is used in treating bacterial and parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

Ramesh Krishnamurthy, CEO of Vivimed Labs said: We are very excited to receive approval to Vivimed's own products. Vivimed strategy is to increase its share of Branded products in CIS Markets. Vivimed shall be launching these products in 2021. Our purpose is to offer innovative & top quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy.

Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.

On a consolidated basis, Vivimed Labs posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.

Powered by Capital Market - Live News

Vivimed Labs announced that its FDF manufacturing facility located in Jeedimetla, near Hyderabad inspected in August 2017 by the Ukraine ministry of Health, has been approved and accredited with GMP Certification effective September 2017 and same has been renewed upto 04 February 2022 on 10 February 2021. Ukraine is a member Country of PICS, whose members include many European Countries.

The GMP approval extension also includes 5 new product registrations.

Powered by Capital Market - Live News

Vivimed Labs announced that its FDF manufacturing facility located in Jeedimetla, near Hyderabad inspected in August 2017 by the Ukraine Ministry of Health, has been approved and accredited with GMP Certification effective September 2017 and same has been renewed upto 4 February 2022 on 10 February 2021. The GMP approval extension also includes 5 new product registrations.

Ukraine is a member Country of PICS, whose members include many European Countries.

Ramesh Krishnamurthy, CEO of Vivimed Labs said: Successful renewal of PICS GMP Certification enables Vivimed to scale up its branded product distribution in CIS Countries. Export thrust is key contributor to the growth strategy of Vivimed.

Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.

On a consolidated basis, Vivimed Labs posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.

Powered by Capital Market - Live News